This report provides an analysis on DCT's/Virtual trials.
Key Highlights
- DCT usage is on the rise
- North America has conducted the most DCTs
- Mobile Healthcare is the top virtual component used
Scope
- The clinical trial data used for these analyses were extracted from the publisher's Clinical Trials Database. The report focuses on DCT trials that were initiated between 2001 to 2022
- The data have been analyzed by year, phase, status, therapy area, indication, geography, sponsor type (top industry sponsors versus non-industry sponsors), and reasons for discontinuation. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively
Reasons to Buy
- Provides a breakdown of DCT's across a number of clinical trial sectors
- Identifies which areas are using DCT's the most
- Highlights the use of DCT's in the industry and against institutional sponsors
Table of Contents
- Executive Summary
- Introduction
- Report Scope
- Methodology
- Clinical Trials Landscape of Real-World Evidence Trials
- The Largest Proportion of DCTs Are in Phase II
- Mobile Healthcare Is a Key Virtual Trial Component for DCTs
- North America Leads for DCTs
- North America Dominates for All Virtual Components
- North America leads Single-Country DCTs, Followed by Europe and Asia-Pacific
- US Leads DCT Usage
- Central Nervous System Is the Most Researched Therapy Area for DCTs
- Type 2 Diabetes Is the Most Researched Indication for DCTs
- Low Accrual Rate Is the Leading Cause of Trial Termination
- More Industry Trials Achieve Their Endpoints
- GSK Is the Top Industry Sponsor for DCTs
- Duke University Is the Top Non-Industry Sponsor for DCTs
- Key Findings
- Appendix
Figure 1: Number of DCTs by sponsor type and year
Figure 2: DCTs by phase and status
Figure 3: Virtual trial components by status
Figure 4: DCTs by regional distribution
Figure 5: Virtual components by region
Figure 6: Single-country and multinational DCTs by region
Figure 7: Distribution of DCTs by top five countries
Figure 8: DCTs by therapy area
Figure 9: DCTs by indication
Figure 10: Reasons for trial discontinuation of DCTs
Figure 11: Completed trials endpoint status, by sponsor type
Figure 12: Top industry sponsors for DCTs
Figure 13: Top non-industry sponsors for DCTs
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis
- GSK
- Pfizer
- Sanofi
- Novo Nordisk
- Takeda Pharmaceutical
- Boehringer Ingelheim Johnson & Johnson
- AstraZeneca
- Eli Lilly
